

**Request for Prior Authorization**  
**ANTIEMETIC-5HT3 RECEPTOR ANTAGONISTS/**  
**SUBSTANCE P NEUROKININ PRODUCTS**

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB
Patient address		
Provider NPI	Prescriber name	Phone
Prescriber address		
Pharmacy name	Address	Phone
<b>Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.</b>		
Pharmacy NPI	Pharmacy fax	NDC

**Prior authorization is required for preferred Antiemetic-5HT3 Receptor Antagonists/Substance P Neurokinin medications for quantities exceeding the dosage limits provided in parentheses. Payment for Antiemetic-5HT3 Receptor Agonists/Substance P Neurokinin Agents beyond this limit will be considered on an individual basis after review of submitted documentation.**

**Prior authorization will be required for all non-preferred Antiemetic-5HT3 Receptor Antagonists/ Substance P Neurokinin medications beginning the first day of therapy. Payment for non-preferred medications will be authorized only for cases in which there is documentation of previous trial(s) and therapy failure with a preferred agent in this class. Note: Aprepitant (Emend®) will only be payable when used in combination with other antiemetic agents (5-HT3 medication and dexamethasone) for patients receiving highly emetogenic cancer chemotherapy.**

**Preferred**

- Ondansetron 4mg tablets (60)
- Ondansetron 8mg tablets (60)
- Ondansetron 2mg/mL (4 – 20mL vials)
- Ondansetron 2mg/mL (8 – 2mL vials)
- Ondansetron ODT 4mg tablets (60)
- Ondansetron ODT 8mg tablets (60)
- Ondansetron oral solution 4mg/5mL (50mL/month)

**Non Preferred**

- Akynzeo (2)
- Anzemet 50mg & 100mg tablets (5)
- Anzemet 100mg/5ml (4 vials)
- Anzemet 12.5mg/0.625ml (8 ampules)
- Aprepitant
- Emend Capsules (80mg (8); 125mg (4))
- Emend Oral Suspension
- Granisetron 1mg tablets (8)
- Sancuso patch

Strength	Dosage Instructions	Quantity	Days Supply
----------	---------------------	----------	-------------

Diagnosis: \_\_\_\_\_

Medical reasoning for therapy exceeding dosage limits: \_\_\_\_\_

Reason for use of Non-Preferred drug requiring prior approval: \_\_\_\_\_

**Attach lab results and other documentation as necessary.**

Prescriber signature (Must match prescriber listed above.)

Date of submission

**IMPORTANT NOTE:** In evaluating requests for prior authorization, the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary, by contact with the county Department of Health and Human Services, that the member continues to be eligible for Medicaid.